Keio, Fujita Medical and CyFuse launch clinical trial of 3D-printed cell knee transplants
Updated
Updated · 매일경제 · Apr 19
Keio, Fujita Medical and CyFuse launch clinical trial of 3D-printed cell knee transplants
9 articles · Updated · 매일경제 · Apr 19
The trial, starting in July in Japan, will transplant 3D-printed cell structures from donor adipose tissue into five patients with idiopathic knee osteonecrosis.
This world-first approach aims to restore both bone and cartilage simultaneously, potentially offering an alternative to artificial knee replacement surgery for thousands of patients annually.
If successful, the technology could be expanded to treat degenerative knee arthritis, affecting up to 30 million people in Japan, and marks a significant advance in regenerative medicine for hard-to-treat joint diseases.
Can 3D-printed living tissue finally offer a true cure for osteoarthritis, not just a treatment?
As Japan and the US race to regenerate joints, who will win the multi-billion dollar battle against arthritis?
With Japan's fast-track approval, what are the real long-term safety risks for these lab-grown joints?
Will this groundbreaking knee repair be affordable for the average person, or only for the wealthy?
If successful, could this technology be used to print other complex organs for transplant?
What happens if a patient's body rejects this 3D-printed, donor-cell-based tissue implant?